Acorda Therapeutics, Inc. (ACOR) Bundle
A Brief History of Acorda Therapeutics, Inc. (ACOR)
Foundation and Initial Developments
Acorda Therapeutics, Inc. was founded in 1995 by Ron Cohen, who aimed to develop therapies for neurological disorders. The company was originally focused on advancing treatments for multiple sclerosis (MS).
Key Products and FDA Approvals
The company's first major product, Ampyra (dalfampridine), was approved by the FDA in January 2010 for improving walking in patients with MS. Ampyra generated significant revenue upon its launch.
In 2019, Acorda received FDA approval for Inbrija (levodopa inhalation powder), a treatment for OFF periods in Parkinson’s disease. This marked a significant enlargement of its product portfolio.
Financial Performance
In 2022, Acorda Therapeutics reported a total revenue of approximately $48.5 million. The revenue from Ampyra alone was about $43.5 million, while Inbrija contributed around $5 million in sales.
The company faced challenges with its financials, reporting a net loss of $147.4 million in the same year.
Stock Performance
Acorda Therapeutics, Inc. trades on the NASDAQ under the ticker symbol ACOR. As of October 2023, the stock price has experienced considerable volatility, fluctuating between a low of $0.28 and a high of $2.30 over the past year.
Research and Development
The company has invested heavily in R&D, amounting to $86 million in 2022, focusing on developing innovative therapies for movement disorders and other neurological conditions.
Table of Key Company Milestones
| Year | Event | Financial Impact |
|---|---|---|
| 1995 | Company Founded | - |
| 2010 | FDA Approval of Ampyra | $48.5 million in revenue (2022) |
| 2019 | FDA Approval of Inbrija | $5 million in revenue (2022) |
| 2022 | Total Revenue Reported | $48.5 million |
| 2022 | Net Loss | $147.4 million |
| 2023 | Stock Price Fluctuation | $0.28 - $2.30 |
Challenges and Strategic Moves
Acorda faced challenges in 2022 concerning drug sales and patent expirations. The company's strategy has included exploring partnerships and seeking to enhance its pipeline of innovative therapies.
Recent Developments
As of October 2023, Acorda Therapeutics is actively pursuing clinical trials for new treatments. The company continues to focus on expanding its reach in the neurotherapeutics market, reinforcing its commitment to patients with debilitating neurological disorders.
A Who Owns Acorda Therapeutics, Inc. (ACOR)
Institutional Ownership
As of the most recent filings, the institutional ownership of Acorda Therapeutics, Inc. stands at approximately 55.2%. Various investment firms and mutual funds hold shares in the company, contributing to its financial stability.
| Institution | Shares Held | % of Total Shares | Type of Institution |
|---|---|---|---|
| Vanguard Group, Inc. | 4,812,299 | 12.8% | Mutual Fund |
| BlackRock, Inc. | 3,948,697 | 10.6% | Mutual Fund |
| State Street Corporation | 2,765,901 | 7.4% | Mutual Fund |
| Geode Capital Management, LLC | 1,028,152 | 2.8% | Hedge Fund |
| Dimensional Fund Advisors, LP | 2,557,310 | 6.9% | Mutual Fund |
Insider Ownership
Insider ownership is another critical component, with insiders owning approximately 10.1% of the total shares. This reflects the personal investment by executives and board members in the company's success.
| Insider | Shares Held | % of Total Shares | Position |
|---|---|---|---|
| Ron Cohen, M.D. | 1,000,000 | 2.7% | President & CEO |
| David A. Karp, M.D. | 250,000 | 0.7% | Chief Medical Officer |
| Additional Executives | 1,350,000 | 3.6% | Various |
Shareholder Structure
The retail ownership constitutes about 34.7% of the total shares outstanding, indicating a diverse ownership landscape that includes both institutional and individual investors.
| Shareholder Type | % Ownership |
|---|---|
| Institutional Investors | 55.2% |
| Insiders | 10.1% |
| Retail Investors | 34.7% |
Recent Stock Performance
The performance of Acorda Therapeutics, Inc. has seen volatility, indicated by a market capitalization of approximately $160 million as of the last trading session, with a current stock price around $1.50 per share.
Recent Financial Data
For the latest fiscal year, Acorda Therapeutics reported revenues of $50 million, with a net loss of $70 million. The company’s operating expenses were approximately $120 million.
| Financial Metric | Value |
|---|---|
| Revenue | $50 million |
| Net Loss | ($70 million) |
| Operating Expenses | $120 million |
Acorda Therapeutics, Inc. (ACOR) Mission Statement
Core Values
Acorda Therapeutics is dedicated to innovative therapies that improve the lives of people with neurological disorders. The mission is centered around the following core values:
- Innovation: Committed to advancing science and developing groundbreaking treatments.
- Integrity: Upholding ethical standards in all operations and interactions.
- Patient-Centric Approach: Focusing on the needs and experiences of patients.
- Collaboration: Working with partners in the medical and scientific communities.
Strategic Objectives
Acorda's strategic objectives are designed to align with their mission and ensure sustainable growth:
- Enhance Pipeline: Aiming to expand the clinical pipeline with new therapies. Current pipeline highlights include:
| Therapy | Indication | Status | Phase |
|---|---|---|---|
| APD-371 | Chronic Pain | In Development | Phase 2 |
| Inbrija | Off-Period Parkinson’s Disease | Marketed | Approved |
Recent Financial Performance
Financial performance is a key indicator of Acorda's ability to fulfill its mission. The report for Q2 2023 includes:
| Financial Metric | Q2 2023 Amount ($ million) | YoY Change (%) |
|---|---|---|
| Total Revenue | 12.3 | -15.7 |
| Net Loss | (3.5) | +20.0 |
| Cash and Cash Equivalents | 25.4 | -10.5 |
Community Engagement and Support
Acorda emphasizes the importance of community and patient support in achieving its mission:
- Patient Advocacy: Partnering with organizations to improve patient access to therapies.
- Educational Initiatives: Conducting workshops and informational sessions for health professionals and patients.
- Diversity and Inclusion: Promoting diverse representation in clinical trials.
Research and Development Focus
The commitment to research and development is integral to Acorda's mission. The R&D budget for 2023 is:
| Category | Budget Allocation ($ million) |
|---|---|
| Neurological Research | 15.0 |
| Clinical Trials | 10.2 |
| Preclinical Studies | 5.8 |
Vision for the Future
Acorda aims to address unmet medical needs through innovation and a focused mission:
- Expansion into International Markets: Exploring opportunities to launch existing products in new regions.
- Partnerships with Biotech Firms: Seeking collaborations to enhance research capabilities.
- Continuous Improvement: Evaluating and refining business strategies to adapt to changing market dynamics.
Conclusion of Mission Alignment
In summary, Acorda Therapeutics' mission is centered on innovation, patient care, and community engagement to transform the lives of individuals affected by neurological disorders. Their strategic direction and financial metrics demonstrate a commitment to these principles.
How Acorda Therapeutics, Inc. (ACOR) Works
Company Overview
Acorda Therapeutics, Inc. (ACOR) is a biotechnology company specializing in developing therapies for neurological disorders. Founded in 1995 and based in Ardsley, New York, Acorda focuses on providing innovative medications to improve the lives of individuals with neurological conditions, particularly multiple sclerosis and Parkinson's disease.
Financial Performance
As of Q3 2023, Acorda Therapeutics reported the following financial data:
| Financial Metric | Q3 2023 Amount (in USD) | Q2 2023 Amount (in USD) | Q1 2023 Amount (in USD) |
|---|---|---|---|
| Total Revenue | $9.1 million | $8.5 million | $7.9 million |
| Net Income (Loss) | ($16.5 million) | ($15.0 million) | ($14.3 million) |
| Operating Expenses | $25.6 million | $24.2 million | $23.7 million |
| Cash and Cash Equivalents | $39.0 million | $48.4 million | $55.2 million |
Product Portfolio
Acorda Therapeutics has a diverse product pipeline targeting neurological conditions. Key products include:
- Ampyra (dalfampridine) - Used to improve walking in adults with multiple sclerosis. Annual sales for Ampyra were approximately $36.2 million in 2022.
- Inbrija (levodopa inhalation powder) - Designed to treat "off" periods in Parkinson's disease. Sales reached $11.1 million in Q3 2023, increasing from $9.7 million in Q2 2023.
- Other Pipeline Candidates - Includes Acorda's investigational therapies targeting unmet needs in neurological disorders.
Research and Development
Acorda allocates a significant portion of its budget to research and development.
| Year | R&D Expenditure (in USD) | % of Total Expenses |
|---|---|---|
| 2021 | $73.3 million | 64% |
| 2022 | $67.8 million | 62% |
| 2023 (Projected) | $65.0 million | 59% |
Market Strategy
Acorda's market strategy includes:
- Targeted marketing efforts for current products in competitive landscapes.
- Collaborations with healthcare professionals and organizations to increase treatment awareness.
- Ongoing clinical trials to enhance product offerings and develop new treatments.
Stock Performance
As of October 2023, Acorda Therapeutics' stock performance is as follows:
| Date | Stock Price (in USD) | Market Capitalization (in USD) |
|---|---|---|
| October 20, 2023 | $1.50 | $86 million |
| September 20, 2023 | $1.45 | $84 million |
| August 20, 2023 | $1.40 | $80 million |
Competitive Landscape
Acorda operates in a competitive environment. Key competitors include:
- Biogen Inc. - Focuses on neurological disorders with multiple marketed therapies.
- AbbVie Inc. - Extensive portfolio including treatments for Parkinson's disease.
- Neurocrine Biosciences, Inc. - Innovative therapies targeting movement disorders.
Recent Developments
Key recent developments impacting Acorda's operations include:
- FDA approval of Inbrija as a treatment for off episodes in Parkinson's disease in 2018.
- Partnerships with research institutions for ongoing clinical trials in neurological therapeutics.
- Initiatives to expand manufacturing capabilities to support product demand.
Conclusion of Financial Indicators
The financial indicators for Acorda highlight ongoing challenges but also potential growth opportunities in a dynamic market.
How Acorda Therapeutics, Inc. (ACOR) Makes Money
Revenue Sources
Acorda Therapeutics, Inc. derives its revenue primarily from the sales of its pharmaceutical products. The company focuses on the development and commercialization of therapies for neurological diseases. In 2021, Acorda reported total revenues of approximately $38.3 million.
Key Products
Acorda has several key products that contribute to its revenue stream:
- Ingrezza (valbenazine) - Approved for the treatment of tardive dyskinesia.
- Ampyra (dalfampridine) - Indicated for gait improvement in patients with multiple sclerosis.
Sales Figures
The following table summarizes the sales figures for Acorda's key products:
| Product | 2021 Sales ($ millions) | 2020 Sales ($ millions) | Growth Rate (%) |
|---|---|---|---|
| Ingrezza | 24.6 | 15.2 | 62.5 |
| Ampyra | 13.7 | 23.1 | -40.5 |
Research and Development
Research and development (R&D) is critical to Acorda’s business strategy. In 2021, the company invested approximately $23.5 million in R&D, focusing on expanding its product pipeline and enhancing existing therapies.
Market Trends
Acorda operates within the neurology market, which is projected to grow significantly. The global market for neurological drugs is expected to reach $134 billion by 2023, influencing Acorda's potential for revenue generation.
Licensing and Collaboration Agreements
Acorda also engages in licensing agreements. The company signed a collaboration agreement with Biogen Inc. for the development and commercialization of therapies. Such agreements can provide additional revenue streams through upfront payments and royalties.
Financial Performance Metrics
The table below provides an overview of key financial performance metrics for Acorda Therapeutics, Inc. for the fiscal year 2021:
| Metric | Value |
|---|---|
| Total Revenue | $38.3 million |
| Net Loss | ($13.7 million) |
| R&D Expenses | $23.5 million |
| Cash and Cash Equivalents | $48.0 million |
Future Outlook
The outlook for Acorda's revenue generation hinges on the successful commercialization of existing products and the development of new therapies. The company’s strategic initiatives include targeting various neurological disorders to expand its market presence.
Acorda Therapeutics, Inc. (ACOR) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support